Skip to content
Archive

KOLINPHARMA®: NEW PATENT IN CHINA FOR DOLTENDIX®

KOLINPHARMA® obtains its first patent in China for DOLTENDIX®.

This brings the total to 49 patents obtained, further strengthening our intellectual property and consolidating our position on the international market.

The granting of the patent in China is a strategic competitive advantage that allows us to protect and enhance a product already successfully marketed in this dynamic market.

DOLTENDIX® is a food supplement formulated for tendon well-being, based on bioactive collagen peptides, astaxanthin, trans-resveratrol and vitamin C.

It is the result of an innovative formulation that shows KOLINPHARMA®’s ongoing commitment to the research and development of cutting-edge solutions aimed at consumer well-being.

We are proud to carry forward Italian excellence in the nutraceutical sector and to help improve people’s well-being.

More news

  1. KOLINPHARMA®: Credit Reputation Award received
  2. KOLINPHARMA® expands its product portfolio with the launch of Kymax®
  3. Kolinpharma® is pleased to announce the launch of KIPFeR®
Archive